As of Mar 04
| +0.055 / +7.86%|
The 1 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median estimate represents a +959.60% increase from the last price of 0.76.
The current consensus among 2 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.